ALBPS.PA

Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.